{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:05:18Z","timestamp":1791255918548,"version":"4.1.0"},"reference-count":152,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Nucleoside analogs (NAs) play a central role in cancer therapy, either through direct cytotoxicity or epigenome reprogramming. They are clinically effective but have shortcomings in their long-term effectiveness because of variable patient responses and the emergence of resistance. There is growing evidence that DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs (ncRNAs) are key factors that determine sensitivity and resistance to NAs. This review summarizes existing evidence on the epigenetic control of cytotoxic and epigenetic nucleoside analogs, discusses predictive biomarkers of human Equilibrative Nucleoside Transporter 1 (hENT1) and deoxycytidine kinase (dCK) promoter methylation, histone modifications, and ncRNA signatures, and assesses the emerging strategies of multi-omic integration. Improvements in detection methods, such as high-resolution sequencing, single-cell profiling, and liquid biopsy, are addressed, along with the issues of reproducibility, tumor heterogeneity, and clinical translation. Epigenetic biomarkers are promising for patient stratification in clinical trials, although a lack of uniformity in technical and methodological approaches currently constrains their full potential. The future focus will be on standardized panels of biomarkers, real-time monitoring, rational combination strategies, and biomarker-directed clinical trial designs. Overall, epigenetic biomarkers are capable of changing nucleoside analog therapy into a more precise, durable, and personalized treatment approach.<\/jats:p>","DOI":"10.3390\/biom16040587","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:25:30Z","timestamp":1776255930000},"page":"587","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Epigenetic Biomarkers for Predicting Nucleoside Analog Drug Response and Resistance in Cancer"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8716-8858","authenticated-orcid":false,"given":"John","family":"Kaszycki","sequence":"first","affiliation":[{"name":"The Division of Medicinal Chemistry, Department of Pharmaceutical Science, School of Pharmacy, The University of Connecticut, Storrs, CT 06269, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6278-0110","authenticated-orcid":false,"given":"Jackson C.","family":"Lin","sequence":"additional","affiliation":[{"name":"The Division of Medicinal Chemistry, Department of Pharmaceutical Science, School of Pharmacy, The University of Connecticut, Storrs, CT 06269, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6402-0518","authenticated-orcid":false,"given":"Minji","family":"Kim","sequence":"additional","affiliation":[{"name":"The Division of Medicinal Chemistry, Department of Pharmaceutical Science, School of Pharmacy, The University of Connecticut, Storrs, CT 06269, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-0412","authenticated-orcid":false,"given":"Hunmin","family":"Jung","sequence":"additional","affiliation":[{"name":"The Division of Medicinal Chemistry, Department of Pharmaceutical Science, School of Pharmacy, The University of Connecticut, Storrs, CT 06269, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1039\/D0NA01084G","article-title":"The evolution of nucleosidic analogues: Self-assembly of prodrugs into nanoparticles for cancer drug delivery","volume":"3","author":"Baroud","year":"2021","journal-title":"Nanoscale Adv."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2741\/4847","article-title":"Epigenetic alterations in cancer","volume":"25","author":"Ilango","year":"2020","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/17474086.2018.1453802","article-title":"Epigenetic therapy: Azacytidine and decitabine in acute myeloid leukemia","volume":"11","author":"Bohl","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bure, I.V., Nemtsova, M.V., and Kuznetsova, E.B. (2022). Histone modifications and non-coding RNAs: Mutual epigenetic regulation and role in pathogenesis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105801"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s12276-023-01020-1","article-title":"Metabolic reprogramming and epigenetic modifications in cancer","volume":"55","author":"Xu","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_6","first-page":"100014","article-title":"Epigenetic modulation in cancer: Molecular mechanisms and therapeutic targets","volume":"1","author":"Safi","year":"2024","journal-title":"Prem. J. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13596-024-00747-0","article-title":"Precision medicine engaging nucleoside analogues","volume":"25","author":"Yehia","year":"2025","journal-title":"Adv. Tradit. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Garner, I.M., and Brown, R. (2022). Is There a Role for Epigenetic Therapies in Modulating DNA Damage Repair Pathways to Enhance Chemotherapy and Overcome Drug Resistance?. Cancers, 14.","DOI":"10.3390\/cancers14061533"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zhan, C., Tang, T., Wu, E., Zhang, Y., He, M., Wu, R., Bi, C., Wang, J., Zhang, Y., and Shen, B. (2023). Multi-omics approaches to personalized medicine in myocardial infarction. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1250340"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Huff, S.E., Winter, J.M., and Dealwis, C.G. (2022). Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. Biomolecules, 12.","DOI":"10.3390\/biom12060815"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kaszycki, J., and Kim, M. (2025). Epigenetic drivers of chemoresistance in nucleobase and nucleoside analog therapies. Biology, 14.","DOI":"10.3390\/biology14070838"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1002\/cpz1.376","article-title":"Overview of marketed nucleoside and nucleotide analogs","volume":"2","author":"Herdewijn","year":"2022","journal-title":"Curr. Protoc."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tsesmetzis, N., Paulin, C.B., Rudd, S.G., and Herold, N. (2018). Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. Cancers, 10.","DOI":"10.3390\/cancers10070240"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1042\/BCJ20230029","article-title":"Mutagenic incorporation of inosine into DNA via T:I mismatch formation by human DNA polymerase eta","volume":"480","author":"Averill","year":"2023","journal-title":"Biochem. J."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Lin, J.C., Averill, J.R., and Jung, H. (2025). Deciphering the Role of DNA Polymerase Eta on the Incorporation and Bypass of Inosine and Cell Cycle Arrest. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262412030"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1093\/nar\/gkae102","article-title":"Novel insights into the role of translesion synthesis polymerase in DNA incorporation and bypass of 5-fluorouracil in colorectal cancer","volume":"52","author":"Averill","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/bloodadvances.2017015214","article-title":"Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase","volume":"2","author":"Fordham","year":"2018","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"Chowdhury","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Plunkett, W., and Gandhi, V. (2021). Nucleoside analogs: Cellular pharmacology and mechanisms. Nucleoside Analogs in Cancer Therapy, CRC Press.","DOI":"10.1201\/9781003067634-1"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pastor-Anglada, M., and P\u00e9rez-Torras, S. (2018). Emerging roles of nucleoside transporters. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00606"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41416-018-0004-2","article-title":"Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer","volume":"118","author":"Elander","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2147\/CMAR.S465098","article-title":"Human equilibrative nucleoside transporter 1: Novel biomarker and prognostic indicator for patients with gemcitabine-treated pancreatic cancer","volume":"16","author":"Xiao","year":"2024","journal-title":"Cancer Manag. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20530","DOI":"10.1038\/s41598-023-47792-4","article-title":"A new technique for the analysis of metabolic pathways of cytidine analogues and cytidine deaminase activities in cells","volume":"13","author":"Koberna","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbrc.2012.03.122","article-title":"DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells","volume":"421","author":"Saiki","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.mam.2007.06.002","article-title":"Targeting base excision repair to improve cancer therapies","volume":"28","author":"Sharma","year":"2007","journal-title":"Mol. Asp. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Khalaf, K., Hana, D., Chou, J.T.T., Singh, C., Mackiewicz, A., and Kaczmarek, M. (2021). Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.656364"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hurra, I.M., Mintoo, M.J., Fatima, K., Kousar, R., Mohiuddin, T., and Khan, S.U. (2024). Tumor microenvironment: Multiway role in drug resistance. Drug Resistance in Cancer: Mechanisms and Strategies, Springer.","DOI":"10.1007\/978-981-97-1666-1_5"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kaszycki, J., and Kim, M. (2025). Epigenetic regulation of transcription factors involved in NLRP3 inflammasome and NF-kB signaling pathways. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1529756"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Amrutkar, M., and Gladhaug, I.P. (2021). Stellate cells aid growth-permissive metabolic reprogramming and promote gemcitabine chemoresistance in pancreatic cancer. Cancers, 13.","DOI":"10.3390\/cancers13040601"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.2174\/0929867325666180403141554","article-title":"Gene silencing strategies in cancer therapy: An update for drug resistance","volume":"26","author":"Naghizadeh","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13148-021-01126-1","article-title":"The dynamic broad epigenetic (H3K4me3, H3K27ac) domain as a mark of essential genes","volume":"13","author":"Beacon","year":"2021","journal-title":"Clin. Epigenet."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Shlyakhtina, Y., Moran, K.L., and Portal, M.M. (2021). Genetic and non-genetic mechanisms underlying cancer evolution. Cancers, 13.","DOI":"10.3390\/cancers13061380"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Giri, A.K., and Aittokallio, T. (2019). DNMT inhibitors increase methylation in the cancer genome. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00385"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.gendis.2018.06.003","article-title":"Epigenetic mechanisms as a new approach in cancer treatment: An updated review","volume":"5","author":"Fardi","year":"2018","journal-title":"Genes Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Thomas, M.L., and Marcato, P. (2018). Epigenetic modifications as biomarkers of tumor development, therapy response, and recurrence across the cancer care continuum. Cancers, 10.","DOI":"10.3390\/cancers10040101"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41416-021-01584-7","article-title":"Unravelling similarities and differences in the role of circular and linear PVT1 in cancer and human disease","volume":"126","author":"Traversa","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Barth, D.A., Juracek, J., Slaby, O., Pichler, M., and Calin, G.A. (2020). lncRNA and mechanisms of drug resistance in cancers of the genitourinary system. Cancers, 12.","DOI":"10.3390\/cancers12082148"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.gendis.2020.07.012","article-title":"Emerging important roles of circRNAs in human cancer and other diseases","volume":"8","author":"Huang","year":"2020","journal-title":"Genes Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s12935-021-02353-5","article-title":"Long noncoding RNA CRART16 confers 5-FU resistance in colorectal cancer cells by sponging miR-193b-5p","volume":"21","author":"Wang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_40","first-page":"3376","article-title":"Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway","volume":"38","author":"Que","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"216640","DOI":"10.1016\/j.canlet.2024.216640","article-title":"CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy","volume":"585","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1002\/1878-0261.13279","article-title":"Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma","volume":"16","author":"Liu","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12032-022-01864-z","article-title":"Regulation of thymidylate synthase: An approach to overcome 5-FU resistance in colorectal cancer","volume":"40","author":"Kumar","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Cui, Z., He, S., Wen, F., Lu, L., Xu, L., Wu, H., and Wu, S. (2023). Dihydropyrimidine dehydrogenase (DPD) as a bridge between the immune microenvironment of colon cancers and 5-FU resistance. Front. Biosci. (Landmark Ed.), 28.","DOI":"10.31083\/j.fbl2804080"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Maiuthed, A., Ninsontia, C., Erlenbach-Wuensch, K., Ndreshkjana, B., Muenzner, J.K., Caliskan, A., Husayn, A.P., Chaotham, C., Hartmann, A., and Roehe, A.V. (2018). Cytoplasmic p21 mediates 5-fluorouracil resistance by inhibiting pro-apoptotic Chk2. Cancers, 10.","DOI":"10.3390\/cancers10100373"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1038\/s41388-020-1352-y","article-title":"SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.taap.2015.11.007","article-title":"Histone deacetylase inhibitor trichostatin A resensitizes gemcitabine-resistant urothelial carcinoma cells via suppression of TG-interacting factor","volume":"290","author":"Yeh","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4251\/wjgo.v3.i11.153","article-title":"Molecular predictors of gemcitabine response in pancreatic cancer","volume":"3","author":"Voutsadakis","year":"2011","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ebiom.2019.05.013","article-title":"HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1","volume":"44","author":"Lu","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.canlet.2013.01.002","article-title":"ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance","volume":"333","author":"Xu","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"118148","DOI":"10.1016\/j.lfs.2020.118148","article-title":"MGMT expression affects the gemcitabine resistance of pancreatic cancer cells","volume":"259","author":"Shi","year":"2020","journal-title":"Life Sci."},{"key":"ref_52","first-page":"2789","article-title":"RV-59 suppresses cytoplasmic Nrf2-mediated 5-fluorouracil resistance and tumor growth in colorectal cancer","volume":"9","author":"Shen","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1055\/a-1525-1499","article-title":"Allicin reduces 5-fluorouracil-resistance in gastric cancer cells through modulating MDR1, DKK1, and WNT5A expression","volume":"71","author":"Khakbaz","year":"2021","journal-title":"Drug Res."},{"key":"ref_54","first-page":"323","article-title":"TFAP2E methylation promotes 5-fluorouracil resistance via exosomal miR-106a-5p and miR-421 in gastric cancer MGC-803 cells","volume":"20","author":"Sun","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.3748\/wjg.v13.i34.4593","article-title":"Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis","volume":"13","author":"Ishida","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1111\/cas.14532","article-title":"5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes","volume":"111","author":"Blondy","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_57","first-page":"2869","article-title":"MiR-519d reduces the 5-fluorouracil resistance in colorectal cancer cells by down-regulating the expression of CCND1","volume":"22","author":"Huang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Baharudin, R., Ab Mutalib, N.-S., Othman, S.N., Sagap, I., Rose, I.M., Mohd Mokhtar, N., and Jamal, R. (2017). Identification of predictive DNA methylation biomarkers for chemotherapy response in colorectal cancer. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00047"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Buocikova, V., Tyciakova, S., Pilalis, E., Mastrokalou, C., Urbanova, M., Matuskova, M., Demkova, L., Medova, V., Longhin, E.M., and Rund\u00e9n-Pran, E. (2022). Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpression. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.991751"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Sorrentino, V.G., Thota, S., Gonzalez, E.A., Rameshwar, P., Chang, V.T., and Etchegaray, J.P. (2021). Hypomethylating chemotherapeutic agents as therapy for myelodysplastic syndromes and prevention of acute myeloid leukemia. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070641"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Romero-Garcia, S., Prado-Garcia, H., and Carlos-Reyes, A. (2020). Role of DNA methylation in the resistance to therapy in solid tumors. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01152"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Youn, A., Kim, K.I., Rabadan, R., Tycko, B., Shen, Y., and Wang, S. (2018). A pan-cancer analysis of driver gene mutations, DNA methylation and gene expressions reveals that chromatin remodeling is a major mechanism inducing global changes in cancer epigenomes. BMC Med. Genom., 11.","DOI":"10.1186\/s12920-018-0425-z"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Gezer, U., \u00d6zg\u00fcr, E., Y\u00f6r\u00fcker, E.E., Polatoglou, E., Holdenrieder, S., and Bronkhorst, A. (2024). LINE-1 cfDNA methylation as an emerging biomarker in solid cancers. Cancers, 16.","DOI":"10.3390\/cancers16223725"},{"key":"ref_64","unstructured":"Kusch, N. (2021). Two-Step Models for Tumour-Drug Response Using Heterogeneous High-Dimensional Assays. [Ph.D. Thesis, Rheinisch-Westf\u00e4lische Technische Hochschule]."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41580-019-0143-1","article-title":"The roles of DNA, RNA and histone methylation in ageing and cancer","volume":"20","author":"Michalak","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/em.22319","article-title":"Mitochondrial DNA: Epigenetics and environment","volume":"60","author":"Sharma","year":"2019","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1104\/pp.19.00988","article-title":"Histone modifications form epigenetic regulatory networks to regulate abiotic stress response","volume":"182","author":"Ueda","year":"2020","journal-title":"Plant Physiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41392-024-02030-9","article-title":"Chromatin accessibility: Biological functions, molecular mechanisms and therapeutic application","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ozyerli-Goknar, E., and Bagci-Onder, T. (2021). Epigenetic deregulation of apoptosis in cancers. Cancers, 13.","DOI":"10.3390\/cancers13133210"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","article-title":"Mechanisms of action and resistance in histone methylation-targeted therapy","volume":"627","author":"Yamagishi","year":"2024","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41580-021-00398-y","article-title":"The molecular principles of gene regulation by Polycomb repressive complexes","volume":"22","author":"Blackledge","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Paradise, B.D., Barham, W., and Fernandez-Zapico, M.E. (2018). Targeting epigenetic aberrations in pancreatic cancer, a new path to improve patient outcomes?. Cancers, 10.","DOI":"10.3390\/cancers10050128"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Quagliano, A., Gopalakrishnapillai, A., and Barwe, S.P. (2020). Understanding the mechanisms by which epigenetic modifiers avert therapy resistance in cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00992"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Hontecillas-Prieto, L., Flores-Campos, R., Silver, A., De \u00c1lava, E., Hajji, N., and Garc\u00eda-Dom\u00ednguez, D.J. (2020). Synergistic enhancement of cancer therapy using HDAC inhibitors: Opportunity for clinical trials. Front. Genet., 11.","DOI":"10.3389\/fgene.2020.578011"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2017.10.015","article-title":"Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo","volume":"413","author":"Wen","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13072-025-00590-w","article-title":"Chromatin remodeling and cancer: The critical influence of the SWI\/SNF complex","volume":"18","author":"Hao","year":"2025","journal-title":"Epigenet. Chromatin"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12935-022-02757-x","article-title":"SWI\/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: A pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases","volume":"22","author":"Li","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s12551-024-01183-9","article-title":"DNA damage and repair in the nucleosome: Insights from computational methods","volume":"16","author":"Gillet","year":"2024","journal-title":"Biophys. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Ozair, A., Bhat, V., Alisch, R.S., Khosla, A.A., Kotecha, R.R., Odia, Y., McDermott, M.W., and Ahluwalia, M.S. (2023). DNA methylation and histone modification in low-grade gliomas: Current understanding and potential clinical targets. Cancers, 15.","DOI":"10.3390\/cancers15041342"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Mehrmohamadi, M., Sepehri, M.H., Nazer, N., and Norouzi, M.R. (2021). A comparative overview of epigenomic profiling methods. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.714687"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/epi-2023-0235","article-title":"Epigenetic signaling and crosstalk in regulation of gene expression and disease progression","volume":"15","author":"Manna","year":"2023","journal-title":"Epigenomics"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/gb-2013-14-3-r25","article-title":"Redistribution of H3K27me3 upon DNA hypomethylation results in de-repression of Polycomb target genes","volume":"14","author":"Reddington","year":"2013","journal-title":"Genome Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00018-017-2596-8","article-title":"Orchestration of H3K27 methylation: Mechanisms and therapeutic implication","volume":"75","author":"Pan","year":"2018","journal-title":"Cell Mol. Life Sci."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Pettini, F., Visibelli, A., Cicaloni, V., Iovinelli, D., and Spiga, O. (2021). Multi-omics model applied to cancer genetics. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115751"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2217\/pgs-2019-0089","article-title":"miRNAs in drug response variability: Potential utility as biomarkers for personalized medicine","volume":"20","author":"Latini","year":"2019","journal-title":"Pharmacogenomics"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13148-019-0757-3","article-title":"Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer\u2014A clinical biomarker discovery and validation study","volume":"11","author":"Jensen","year":"2019","journal-title":"Clin. Epigenet."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Wang, G., Li, Y., Lei, D., Xiang, J., Ouyang, L., Wang, Y., and Yang, J. (2022). Recent progress in DNA methyltransferase inhibitors as anticancer agents. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1072651"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3329\/ajmbr.v11i2.79668","article-title":"The role of DNA methylation and histone modifications in the pathogenesis of hematological malignancies and solid cancers: Mechanisms, clinical implications, and therapeutic potential","volume":"11","author":"Rehman","year":"2025","journal-title":"Asian J. Med. Biol. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.18632\/oncotarget.26877","article-title":"The histone deacetylase inhibitor Romidepsin induces a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells","volume":"10","author":"Clarke","year":"2019","journal-title":"Oncotarget"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"215899","DOI":"10.1016\/j.canlet.2022.215899","article-title":"DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma","volume":"548","author":"Zhang","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10555-016-9628-y","article-title":"Deciphering the function of non-coding RNAs in prostate cancer","volume":"35","author":"Fromm","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"19280","DOI":"10.1002\/jcp.28607","article-title":"The potential role of miR-29 in health and cancer diagnosis, prognosis, and therapy","volume":"234","author":"Alizadeh","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"148044","DOI":"10.1016\/j.gene.2023.148044","article-title":"LINC00319: Unraveling the spectrum from gene regulation to clinical applications in cancer progression","volume":"896","author":"Su","year":"2024","journal-title":"Gene"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Yuan, Y., Tang, Y., Fang, Z., Wen, J., Wicha, M.S., and Luo, M. (2025). Long non-coding RNAs: Key regulators of tumor epithelial\/mesenchymal plasticity and cancer stemness. Cells, 14.","DOI":"10.3390\/cells14030227"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Lemus, E., and Ochoa, S. (2024). Methods for multi-omic data integration in cancer research. Front. Genet., 15.","DOI":"10.3389\/fgene.2024.1425456"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"151456","DOI":"10.1016\/j.semperi.2021.151456","article-title":"Multi \u2018omic data integration: A review of concepts, considerations, and approaches","volume":"45","author":"Hollister","year":"2021","journal-title":"Semin Perinatol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Desaulniers, D., Vasseur, P., Jacobs, A., Aguila, M.C., Ertych, N., and Jacobs, M.N. (2021). Integration of epigenetic mechanisms into non-genotoxic carcinogenicity hazard assessment: Focus on DNA methylation and histone modifications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222010969"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev-pathol-042220-022304","article-title":"DNA methylation profiling: An emerging paradigm for cancer diagnosis","volume":"17","author":"Aldape","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Kundu, S., Das, R., Laskar, S., Choudhury, Y., and Ghosh, S.K. (2020). Principles of bi-sulfite conversion of DNA and methylation-specific PCR (MSP) in biological research. Epigenetics Methods, Academic Press.","DOI":"10.1016\/B978-0-12-819414-0.00002-1"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13059-016-1066-1","article-title":"Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling","volume":"17","author":"Pidsley","year":"2016","journal-title":"Genome Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1080\/15592294.2020.1827703","article-title":"Genome-wide DNA methylation profiling in human breast tissue by Illumina TruSeq methyl capture EPIC sequencing and Infinium MethylationEPIC BeadChip microarray","volume":"16","author":"Lin","year":"2021","journal-title":"Epigenetics"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41576-018-0089-8","article-title":"Chromatin accessibility and the regulatory epigenome","volume":"20","author":"Klemm","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Sepehri, Z., Beacon, T.H., Osman, F.D., Jahan, S., and Davie, J.R. (2019). DNA methylation and chromatin modifications. Nutritional Epigenomics, Elsevier.","DOI":"10.1016\/B978-0-12-816843-1.00002-3"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41596-024-01058-z","article-title":"Multiplexed chromatin immunoprecipitation sequencing for quantitative study of histone modifications and chromatin factors","volume":"20","author":"Kumar","year":"2025","journal-title":"Nat. Protoc."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e1465","DOI":"10.1002\/wsbm.1465","article-title":"Going low to reach high: Small-scale ChIP-seq maps new terrain","volume":"12","author":"Fosslie","year":"2020","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/dvdy.430","article-title":"Identification of chromatin states during zebrafish gastrulation using CUT&RUN and CUT&Tag","volume":"251","author":"Duval","year":"2022","journal-title":"Dev. Dyn."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Tsoneva, D.K., Ivanov, M.N., Conev, N.V., Manev, R., Stoyanov, D.S., and Vinciguerra, M. (2023). Circulating histones to detect and monitor the progression of cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24020942"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Baumann, A.A., Buribayev, Z., Wolkenhauer, O., Salybekov, A.A., and Wolfien, M. (2025). Epigenomic echoes\u2014Decoding genomic and epigenetic instability to distinguish lung cancer types and predict relapse. Epigenomes, 9.","DOI":"10.3390\/epigenomes9010005"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Micheel, J., Safrastyan, A., and Wollny, D. (2021). Advances in non-coding RNA sequencing. Noncoding RNA, 7.","DOI":"10.3390\/ncrna7040070"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Dai, R., Wang, Z., and Ahmed, S.A. (2021). Epigenetic contribution and genomic imprinting Dlk1-Dio3 miRNAs in systemic lupus erythematosus. Genes, 12.","DOI":"10.3390\/genes12050680"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Nguyen, T.T., Suman, K.H., Nguyen, T.B., Nguyen, H.T., and Do, D.N. (2022). The role of miR-29s in human cancers\u2014An update. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092121"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.omtm.2021.12.007","article-title":"Consensus guidelines for the validation of qRT-PCR assays in clinical research by the CardioRNA consortium","volume":"24","author":"Marchese","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Garbo, E., Del Rio, B., Ferrari, G., Cani, M., Napoli, V.M., Bertaglia, V., Capelletto, E., Rolfo, C., Novello, S., and Passiglia, F. (2023). Exploring the potential of non-coding RNAs as liquid biopsy biomarkers for lung cancer screening: A literature review. Cancers, 15.","DOI":"10.3390\/cancers15194774"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41416-021-01672-8","article-title":"Non-coding RNAs as liquid biopsy biomarkers in cancer","volume":"126","author":"Toden","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Shaw","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41576-020-00300-0","article-title":"The epigenetic basis of cellular heterogeneity","volume":"22","author":"Carter","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s12033-024-01133-6","article-title":"From data to cure: A comprehensive exploration of multi-omics data analysis for targeted therapies","volume":"67","author":"Mukherjee","year":"2025","journal-title":"Mol. Biotechnol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1021\/prechem.5c00014","article-title":"Advances in epigenomic sequencing and their applications in cancer diagnostics","volume":"3","author":"Lin","year":"2025","journal-title":"Precis. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13148-021-01002-y","article-title":"Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival","volume":"13","author":"Malinverni","year":"2021","journal-title":"Clin. Epigenet."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/cts.13548","article-title":"DNA methyltransferase inhibitor exposure response: Challenges and opportunities","volume":"16","author":"Kagan","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13148-025-01856-6","article-title":"Epigenetic regulators combined with tumour immunotherapy: Current status and perspectives","volume":"17","author":"Zhang","year":"2025","journal-title":"Clin. Epigenet."},{"key":"ref_122","first-page":"741","article-title":"Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia","volume":"6","author":"Cross","year":"2013","journal-title":"OncoTargets Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"188722","DOI":"10.1016\/j.bbcan.2022.188722","article-title":"DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer","volume":"1877","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Ponomaryova, A.A., Rykova, E.Y., Gervas, P.A., Cherdyntseva, N.V., Mamedov, I.Z., and Azhikina, T.L. (2020). Aberrant methylation of LINE-1 transposable elements: A search for cancer biomarkers. Cells, 9.","DOI":"10.3390\/cells9092017"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3324\/haematol.2013.099549","article-title":"Why methylation is not a marker predictive of response to hypomethylating agents","volume":"99","author":"Voso","year":"2014","journal-title":"Haematologica"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Perrier, A., Didelot, A., Laurent-Puig, P., Blons, H., and Garinet, S. (2020). Epigenetic mechanisms of resistance to immune checkpoint inhibitors. Biomolecules, 10.","DOI":"10.3390\/biom10071061"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1177271919846454","DOI":"10.1177\/1177271919846454","article-title":"Oncogenic roles and inhibitors of DNMT1, DNMT3A, and DNMT3B in acute myeloid leukaemia","volume":"14","author":"Wong","year":"2019","journal-title":"Biomark. Insights"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Liu, P., Yang, F., Zhang, L., Hu, Y., Chen, B., Wang, J., Su, L., Wu, M., and Chen, W. (2022). Emerging role of different DNA methyltransferases in the pathogenesis of cancer. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.958146"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1039\/D3AN01915B","article-title":"A review on recent advances in assays for DNMT1: A promising diagnostic biomarker for multiple human cancers","volume":"149","author":"Yu","year":"2024","journal-title":"Analyst"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrg.2016.93","article-title":"Targeting the cancer epigenome for therapy","volume":"17","author":"Jones","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","article-title":"Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance","volume":"10","author":"Song","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_132","first-page":"589","article-title":"Histone modifications and cancer: Biomarkers of prognosis?","volume":"2","author":"Chervona","year":"2012","journal-title":"Am. J. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1158\/0008-5472.CAN-05-2481","article-title":"Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state","volume":"66","author":"McGarvey","year":"2006","journal-title":"Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Su\u00e1rez, B., Sol\u00e9, C., M\u00e1rquez, M., Nanetti, F., and Henderson Lawrie, C.H. (2022). Circulating MicroRNAs as Cancer Biomarkers in Liquid Biopsies, Springer.","DOI":"10.1007\/978-3-031-08356-3_2"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa074256","article-title":"MicroRNA expression in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Marcucci","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/bloodadvances.2023011583","article-title":"RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia","volume":"8","author":"Kubota","year":"2024","journal-title":"Blood Adv."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Zsid\u00f3, B.Z., and Het\u00e9nyi, C. (2020). Molecular structure, binding affinity, and biological activity in the epigenome. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21114134"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e2404058121","DOI":"10.1073\/pnas.2404058121","article-title":"Histone modifications of circulating nucleosomes are associated with changes in cell-free DNA fragmentation patterns","volume":"121","author":"Bai","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13046-025-03391-x","article-title":"MicroRNA in cancer therapy: Breakthroughs and challenges in early clinical applications","volume":"44","author":"Martino","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Grishina, O., Schmoor, C., D\u00f6hner, K., Hackanson, B., Lubrich, B., May, A.M., Cieslik, C., M\u00fcller, M.J., and L\u00fcbbert, M. (2015). DECIDER: Prospective randomized multicenter phase II trial of low-dose decitabine administered alone or in combination with the histone deacetylase inhibitor valproic acid and all-trans retinoic acid in patients > 60 years with acute myeloid leukemia who are ineligible for induction chemotherapy. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1432-5"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/cac2.12326","article-title":"DNA methylation signature predicts cancer response to demethylation agents from profiling diverse cancer cell lines","volume":"42","author":"Sun","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13148-023-01596-5","article-title":"Long-term decitabine\/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics","volume":"15","author":"Javorniczky","year":"2023","journal-title":"Clin. Epigenet."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13148-021-01098-2","article-title":"Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy","volume":"13","author":"Yang","year":"2021","journal-title":"Clin. Epigenet."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/cts.12960","article-title":"A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and\/or microsatellite instability phenotype","volume":"14","author":"Baretti","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1158\/1078-0432.CCR-20-3946","article-title":"Phase I trial of DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine for solid malignancies including urothelial carcinoma (SPIRE)","volume":"27","author":"Crabb","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome\u2014Biological and translational implications","volume":"11","author":"Baylin","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13148-024-01806-8","article-title":"Clinical promise and applications of epigenetic biomarkers","volume":"16","author":"Wisman","year":"2024","journal-title":"Clin. Epigenet."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40364-019-0174-y","article-title":"Epigenetic heterogeneity in cancer","volume":"7","author":"Guo","year":"2019","journal-title":"Biomark. Res."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Horgan, D., Hamdi, Y., Lal, J.A., Nyawira, T., Meyer, S., Kondji, D., Francisco, N.M., De Guzman, R., Paul, A., and Bernard, B. (2023). Framework for adoption of next-generation sequencing (NGS) globally in the oncology area. Healthcare, 11.","DOI":"10.3390\/healthcare11030431"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/4\/587\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:38:31Z","timestamp":1776256711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/4\/587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":152,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["biom16040587"],"URL":"https:\/\/doi.org\/10.3390\/biom16040587","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}